Abstract
Interleukin-2 (IL-2) immunotherapy resulted in the development of inflammatory arthritis in three male patients with metastatic cancer. Two patients developed a clinical picture consistent with rheumatoid arthritis. A third patient with a remote history of Reiter's syndrome developed a recrudescence of an inflammatory arthritis after treatment with IL-2. The clinical, laboratory, and histologic data on the patients and the potential pathophysiologic mechanisms are discussed.
Publication types
-
Case Reports
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Antibodies, Antinuclear / blood
-
Arthritis / blood
-
Arthritis / chemically induced*
-
Arthritis / immunology
-
Arthritis, Reactive / complications
-
Biopsy
-
Histocompatibility Testing
-
Humans
-
Interleukin-2 / administration & dosage
-
Interleukin-2 / adverse effects*
-
Male
-
Middle Aged
-
Neoplasms / physiopathology
-
Neoplasms / therapy
-
Phenotype
-
Remission Induction
-
Rheumatoid Factor / blood
-
Synovial Fluid / chemistry
-
Synovial Membrane / pathology
Substances
-
Antibodies, Antinuclear
-
Interleukin-2
-
Rheumatoid Factor